{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:31:34Z","timestamp":1781505094591,"version":"3.54.1"},"reference-count":223,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40265-018-0891-9","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T09:29:11Z","timestamp":1521710951000},"page":"621-641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Individualising Therapy to Minimize Bacterial Multidrug Resistance"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-9812","authenticated-orcid":false,"given":"A. J.","family":"Heffernan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. B.","family":"Sime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,22]]},"reference":[{"key":"891_CR1","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jinf.2016.07.002","volume":"73","author":"MJ Satlin","year":"2016","unstructured":"Satlin MJ, Cohen N, Ma KC, Gedrimaite Z, Soave R, Askin G, et al. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J Infect. 2016;73:336\u201345.","journal-title":"J Infect."},{"key":"891_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1469-0691.2011.03478.x","volume":"18","author":"D Ben-David","year":"2012","unstructured":"Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18:54\u201360.","journal-title":"Clin Microbiol Infect."},{"key":"891_CR3","first-page":"243","volume":"198","author":"DFM Looke","year":"2013","unstructured":"Looke DFM, Gottlieb T, Jones CA, Paterson DL. Gram-negative resistance: can we combat the coming of a new \u201cRed Plague\u201d? MJA. 2013;198:243\u20134.","journal-title":"MJA."},{"key":"891_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S1473-3099(11)70059-7","volume":"11","author":"TR Walsh","year":"2011","unstructured":"Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011;11:355\u201362.","journal-title":"Lancet Infect Dis."},{"key":"891_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.7326\/M16-0291","volume":"165","author":"D Deak","year":"2016","unstructured":"Deak D, Outterson K, Powers JH, Kesselheim AS. Progress in the fight against multidrug-resistant bacteria? A review of US Food and Drug Administration-Approved Antibiotics, 2010\u20132015. Ann Intern Med. 2016;165:363\u201372.","journal-title":"Ann Intern Med."},{"key":"891_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/01.CCM.0000249826.81273.E4","volume":"35","author":"A Combes","year":"2007","unstructured":"Combes A, Luyt CE, Fagon JY, Wolff M, Trouillet JL, Chastre J, et al. Early predictors for infection recurrence and death in patients with ventilator-associated pneumonia. Crit Care Med. 2007;35:146\u201354.","journal-title":"Crit Care Med."},{"key":"891_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ijantimicag.2012.05.005","volume":"40","author":"F Fernandez-Cuenca","year":"2012","unstructured":"Fernandez-Cuenca F, Gomez-Sanchez M, Rodriguez-Bano J, Martinez-Martinez L, Vila J, Bou G, et al. Epidemiological and clinical features associated with colonisation\/infection by Acinetobacter baumannii with phenotypic heterogeneous resistance to carbapenems. Int J Antimicrob Agents. 2012;40:235\u20138.","journal-title":"Int J Antimicrob Agents."},{"key":"891_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1055\/s-0034-1398490","volume":"36","author":"MH Abdul-Aziz","year":"2015","unstructured":"Abdul-Aziz MH, Lipman J, Mouton JW, Hope WW, Roberts JA. Applying pharmacokinetic\/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med. 2015;36:136\u201353.","journal-title":"Semin Respir Crit Care Med."},{"key":"891_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12916-017-0795-7","volume":"15","author":"R Sager","year":"2017","unstructured":"Sager R, Kutz A, Mueller B, Schuetz P. Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Med. 2017;15:11.","journal-title":"BMC Med."},{"key":"891_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0140-6736(09)61879-1","volume":"375","author":"L Bouadma","year":"2010","unstructured":"Bouadma L, Luyt C-E, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients\u2019 exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375:463\u201374.","journal-title":"Lancet."},{"key":"891_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/MCC.0000000000000229","volume":"21","author":"D Tsai","year":"2015","unstructured":"Tsai D, Lipman J, Roberts JA. Pharmacokinetic\/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill. Curr Opin Crit Care. 2015;21:412\u201320.","journal-title":"Curr Opin Crit Care."},{"key":"891_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1183\/09031936.00149508","volume":"34","author":"F Scaglione","year":"2009","unstructured":"Scaglione F, Esposito S, Leone S, Lucini V, Pannacci M, Ma L, et al. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur Resp J. 2009;34:394\u2013400.","journal-title":"Eur Resp J."},{"key":"891_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498\u2013509.","journal-title":"Lancet Infect Dis."},{"key":"891_CR14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","volume":"37","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37:840\u201351.","journal-title":"Crit Care Med."},{"key":"891_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1086\/510590","volume":"44","author":"TP Lodise Jr","year":"2007","unstructured":"Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44:357\u201363.","journal-title":"Clin Infect Dis."},{"key":"891_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","volume":"194","author":"JA Roberts","year":"2016","unstructured":"Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, et al. Continuous versus intermittent beta-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194:681\u201391.","journal-title":"Am J Respir Crit Care Med."},{"key":"891_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","volume":"26","author":"WA Craig","year":"1998","unstructured":"Craig WA. Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1\u201310.","journal-title":"Clin Infect Dis."},{"key":"891_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","volume":"155","author":"RD Moore","year":"1987","unstructured":"Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93\u20139.","journal-title":"J Infect Dis."},{"key":"891_CR19","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/jac\/dku569","volume":"70","author":"O Pajot","year":"2015","unstructured":"Pajot O, Burdet C, Couffignal C, Massias L, Armand-Lefevre L, Foucrier A, et al. Impact of imipenem and amikacin pharmacokinetic\/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia. J Antimicrob Chemother. 2015;70:1487\u201394.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR20","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1128\/AAC.01468-07","volume":"52","author":"VH Tam","year":"2008","unstructured":"Tam VH, Ledesma KR, Vo G, Kabbara S, Lim TP, Nikolaou M. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Antimicrob Agents Chemother. 2008;52:3987\u201393.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR21","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/jac\/dkg403","volume":"52","author":"SA Zelenitsky","year":"2003","unstructured":"Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother. 2003;52:668\u201374.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR22","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0149-2918(01)80103-X","volume":"23","author":"PF Smith","year":"2001","unstructured":"Smith PF, Ballow CH, Booker BM, Forrest A, Schentag JJ. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther. 2001;23:1231\u201344.","journal-title":"Clin Ther."},{"key":"891_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1440-1681.2012.05715.x","volume":"39","author":"MG Sinnollareddy","year":"2012","unstructured":"Sinnollareddy MG, Roberts MS, Lipman J, Roberts JA. \u03b2-Lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review. Clin Exp Pharmacol Physiol. 2012;39:489\u201396.","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"891_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","volume":"17","author":"WA Craig","year":"2003","unstructured":"Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 2003;17:479\u2013501.","journal-title":"Infect Dis Clin North Am."},{"key":"891_CR25","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.1128\/AAC.00867-13","volume":"57","author":"TW Felton","year":"2013","unstructured":"Felton TW, Goodwin J, O\u2019Connor L, Sharp A, Gregson L, Livermore J, et al. Impact of bolus dosing versus continuous infusion of piperacillin and tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013;57:5811\u20139.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/mdr.2008.0783","volume":"14","author":"F Cafini","year":"2008","unstructured":"Cafini F, Aguilar L, Sevillano D, Gimenez MJ, Alou L, Fenoll A, et al. Decrease in bacterial load versus resistance selection of pneumococcal subpopulations by beta-lactam physiological concentrations over time: an in vitro pharmacodynamic simulation. Microb Drug Resist. 2008;14:13\u201321.","journal-title":"Microb Drug Resist."},{"key":"891_CR27","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/jac\/dkx001","volume":"72","author":"VH Tam","year":"2017","unstructured":"Tam VH, Chang KT, Zhou J, Ledesma KR, Phe K, Gao S, et al. Determining beta-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. J Antimicrob Chemother. 2017;72:1421\u20138.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR28","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1128\/AAC.49.12.4920-4927.2005","volume":"49","author":"VH Tam","year":"2005","unstructured":"Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. Optimization of meropenem minimum concentration\/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49:4920\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR29","doi-asserted-by":"publisher","first-page":"6773","DOI":"10.1128\/AAC.03505-14","volume":"58","author":"X Li","year":"2014","unstructured":"Li X, Wang L, Zhang XJ, Yang Y, Gong WT, Xu B, et al. Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model. Antimicrob Agents Chemother. 2014;58:6773\u201381.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR30","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/jac\/dkq211","volume":"65","author":"SA Zelenitsky","year":"2010","unstructured":"Zelenitsky SA, Ariano RE. Support for higher ciprofloxacin AUC(24)\/MIC targets in treating Enterobacteriaceae bloodstream infection. J Antimicrob Chemother. 2010;65:1725\u201332.","journal-title":"J Antimicrob Chemother"},{"key":"891_CR31","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","volume":"37","author":"A Forrest","year":"1993","unstructured":"Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37:1073\u201381.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR32","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1128\/AAC.40.3.627","volume":"40","author":"KJ Madaras-Kelly","year":"1996","unstructured":"Madaras-Kelly KJ, Ostergaard BE, Hovde LB, Rotschafer JC. Twenty-four-hour area under the concentration-time curve MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 1996;40:627\u201332.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR33","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1128\/AAC.45.10.2793-2797.2001","volume":"45","author":"PG Ambrose","year":"2001","unstructured":"Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2001;45:2793\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR34","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1128\/AAC.00334-06","volume":"51","author":"VH Tam","year":"2007","unstructured":"Tam VH, Louie A, Deziel MR, Liu WG, Drusano GL. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother. 2007;51:744\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR35","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1128\/AAC.47.5.1604-1613.2003","volume":"47","author":"AA Firsov","year":"2003","unstructured":"Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:1604\u201313.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR36","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1093\/jac\/dkl135","volume":"57","author":"SK Olofsson","year":"2006","unstructured":"Olofsson SK, Marcusson LL, Lindgren PK, Hughes D, Cars O. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother. 2006;57:1116\u201321.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR37","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1128\/AAC.01485-12","volume":"57","author":"NE Holmes","year":"2013","unstructured":"Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O\u2019Sullivan MV, et al. Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2013;57:1654\u201363.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR38","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/jac\/dkl387","volume":"58","author":"AA Firsov","year":"2006","unstructured":"Firsov AA, Smirnova MV, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother. 2006;58:1185\u201392.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR39","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1128\/AAC.02657-15","volume":"60","author":"JR Lenhard","year":"2016","unstructured":"Lenhard JR, Brown T, Rybak MJ, Meaney CJ, Norgard NB, Bulman ZP, et al. Sequential evolution of vancomycin-intermediate resistance alters virulence in Staphylococcus aureus: pharmacokinetic\/pharmacodynamic targets for vancomycin exposure. Antimicrob Agents Chemother. 2016;60:1584\u201391.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR40","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","volume":"42","author":"CR Rayner","year":"2003","unstructured":"Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42:1411\u201323.","journal-title":"Clin Pharmacokinet."},{"key":"891_CR41","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijantimicag.2011.05.007","volume":"38","author":"HY Dong","year":"2011","unstructured":"Dong HY, Wang X, Dong YL, Lei JE, Li H, You HS, et al. Clinical pharmacokinetic\/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents. 2011;38:296\u2013300.","journal-title":"Int J Antimicrob Agents."},{"key":"891_CR42","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1093\/jac\/dks201","volume":"67","author":"BT Tsuji","year":"2012","unstructured":"Tsuji BT, Bulitta JB, Brown T, Forrest A, Kelchlin PA, Holden PN, et al. Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. J Antimicrob Chemother. 2012;67:2182\u201390.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR43","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1128\/AAC.05453-11","volume":"56","author":"BT Tsuji","year":"2012","unstructured":"Tsuji BT, Brown T, Parasrampuria R, Brazeau DA, Forrest A, Kelchlin PA, et al. Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus. Antimicrob Agents Chemother. 2012;56:3712\u20139.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR44","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","volume":"48","author":"N Safdar","year":"2004","unstructured":"Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48:63\u20138.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR45","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1093\/jac\/dkq226","volume":"65","author":"RV Dudhani","year":"2010","unstructured":"Dudhani RV, Turnidge JD, Nation RL, Li J. fAUC\/MIC is the most predictive pharmacokinetic\/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother. 2010;65:1984\u201390.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00476-17","author":"AJ Lepak","year":"2017","unstructured":"Lepak AJ, Zhao M, VanScoy B, Taylor DS, Ellis-Grosse E, Ambrose PG, et al. In vivo pharmacokinetics and pharmacodynamics of ZTI-01 (fosfomycin for injection) in the neutropenic murine thigh infection model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.00476-17.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR47","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1128\/AAC.00752-15","volume":"59","author":"F Docobo-Perez","year":"2015","unstructured":"Docobo-Perez F, Drusano GL, Johnson A, Goodwin J, Whalley S, Ramos-Martin V, et al. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrob Agents Chemother. 2015;59:5602\u201310.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR48","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1128\/AAC.00144-06","volume":"50","author":"J Gugel","year":"2006","unstructured":"Gugel J, dos Santos Pereira A, Pignatari ACC, Gales AC. \u03b2-Lactam MICs correlate poorly with mutant prevention concentrations for clinical isolates of Acinetobacter spp. and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50:2276\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR49","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijantimicag.2005.10.005","volume":"27","author":"GT Hansen","year":"2006","unstructured":"Hansen GT, Zhao XL, Drlica K, Blondeau JM. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicrob Agents. 2006;27:120\u20134.","journal-title":"Int J Antimicrob Agents."},{"key":"891_CR50","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1172\/JCI200316814","volume":"112","author":"N Jumbe","year":"2003","unstructured":"Jumbe N. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003;112:275\u201385.","journal-title":"J Clin Invest."},{"key":"891_CR51","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1128\/AAC.00033-10","volume":"54","author":"K Credito","year":"2010","unstructured":"Credito K, Kosowska-Shick K, Appelbaum PC. Mutant prevention concentrations of four carbapenems against gram-negative rods. Antimicrob Agents Chemother. 2010;54:2692\u20135.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR52","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1128\/AAC.00822-15","volume":"59","author":"M Diez-Aguilar","year":"2015","unstructured":"Diez-Aguilar M, Morosini MI, Tedim AP, Rodriguez I, Aktas Z, Canton R. Antimicrobial activity of fosfomycin\u2013tobramycin combination against Pseudomonas aeruginosa isolates assessed by time-kill assays and mutant prevention concentrations. Antimicrob Agents Chemother. 2015;59:6039\u201345.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR53","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ijantimicag.2014.12.034","volume":"45","author":"JM Blondeau","year":"2015","unstructured":"Blondeau JM, Shebelski SD, Hesje CK. Killing of Streptococcus pneumoniae by azithromycin, clarithromycin, erythromycin, telithromycin and gemifloxacin using drug minimum inhibitory concentrations and mutant prevention concentrations. Int J Antimicrob Agents. 2015;45:594\u20139.","journal-title":"Int J Antimicrob Agents."},{"key":"891_CR54","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/infdis\/jiu237","volume":"210","author":"GL Drusano","year":"2014","unstructured":"Drusano GL, Liu W, Fikes S, Cirz R, Robbins N, Kurhanewicz S, et al. Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model. J Infect Dis. 2014;210:1319\u201324.","journal-title":"J Infect Dis."},{"key":"891_CR55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1586\/17476348.1.1.7","volume":"1","author":"CK Hesje","year":"2007","unstructured":"Hesje CK, Tillotson GS, Blondeau JM. MICs, MPCs and PK\/PDs: a match (sometimes) made in hosts. Expert Rev Respir Med. 2007;1:7\u201316.","journal-title":"Expert Rev Respir Med."},{"key":"891_CR56","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1086\/511642","volume":"44","author":"K Drlica","year":"2007","unstructured":"Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis. 2007;44:681\u20138.","journal-title":"Clin Infect Dis."},{"key":"891_CR57","doi-asserted-by":"publisher","first-page":"979648","DOI":"10.1155\/2014\/979648","volume":"2014","author":"E Dahdouh","year":"2014","unstructured":"Dahdouh E, Shoucair SH, Salem SE, Daoud Z. Mutant prevention concentrations of imipenem and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii. Sci World J. 2014;2014:979648.","journal-title":"Sci World J."},{"key":"891_CR58","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nprot.2007.521","volume":"3","author":"I Wiegand","year":"2008","unstructured":"Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc. 2008;3:163\u201375.","journal-title":"Nat Protoc."},{"key":"891_CR59","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1128\/JCM.42.1.7-11.2004","volume":"42","author":"MJ Bruins","year":"2004","unstructured":"Bruins MJ, Bloembergen P, Ruijs G, Wolfhagen M. Identification and susceptibility testing of Enterobacteriaceae and Pseudomonas aeruginosa by direct inoculation from positive BACTEC blood culture bottles into Vitek 2. J Clin Microbiol. 2004;42:7\u201311.","journal-title":"J Clin Microbiol."},{"key":"891_CR60","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/ja.2013.87","volume":"66","author":"LG Liu","year":"2013","unstructured":"Liu LG, Zhu YL, Hu LF, Cheng J, Ye Y, Li JB. Comparative study of the mutant prevention concentrations of vancomycin alone and in combination with levofloxacin, rifampicin and fosfomycin against methicillin-resistant Staphylococcus epidermidis. J Antibiot. 2013;66:709\u201312.","journal-title":"J Antibiot."},{"key":"891_CR61","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1128\/AAC.47.8.2606-2614.2003","volume":"47","author":"GP Allen","year":"2003","unstructured":"Allen GP, Kaatz GW, Rybak MJ. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2003;47:2606\u201314.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR62","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/jac\/dkm265","volume":"60","author":"SK Olofsson","year":"2007","unstructured":"Olofsson SK, Marcusson LL, Stromback A, Hughes D, Cars O. Dose-related selection of fluoroquinolone-resistant Escherichia coli. J Antimicrob Chemother. 2007;60:795\u2013801.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR63","unstructured":"Breakpoint tables for interpretation of MICs and zone diameters: The European Committee on Antimicrobial Susceptibility Testing; 2017. http:\/\/eucast.org. Accessed 24 Jan 2017."},{"key":"891_CR64","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00228-014-1766-y","volume":"71","author":"C Burdet","year":"2015","unstructured":"Burdet C, Pajot O, Couffignal C, Armand-Lefevre L, Foucrier A, Laouenan C, et al. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. Eur J Clin Pharmacol. 2015;71:75\u201383.","journal-title":"Eur J Clin Pharmacol."},{"key":"891_CR65","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/jac\/dku354","volume":"70","author":"F Frippiat","year":"2015","unstructured":"Frippiat F, Musuamba FT, Seidel L, Albert A, Denooz R, Charlier C, et al. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. J Antimicrob Chemother. 2015;70:207\u201316.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR66","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04337.x","volume":"75","author":"M Haeseker","year":"2013","unstructured":"Haeseker M, Stolk L, Nieman F, Hoebe C, Neef C, Bruggeman C, et al. The ciprofloxacin target AUC:MIC ratio is not reached in hospitalized patients with the recommended dosing regimens. Br J Clin Pharmacol. 2013;75:180\u20135.","journal-title":"Br J Clin Pharmacol."},{"key":"891_CR67","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01276-16","author":"AS Alobaid","year":"2017","unstructured":"Alobaid AS, Wallis SC, Jarrett P, Starr T, Stuart J, Lassig-Smith M, et al. Population pharmacokinetics of piperacillin in nonobese, obese, and morbidly obese critically ill patients. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.01276-16.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx427","author":"JW Mouton","year":"2017","unstructured":"Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J. MIC-based dose adjustment: facts and fables. J Antimicrob Chemother. 2017. https:\/\/doi.org\/10.1093\/jac\/dkx427.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR69","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1128\/AAC.40.11.2505","volume":"40","author":"J Tankovic","year":"1996","unstructured":"Tankovic J, Perichon B, Duval J, Courvalin P. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother. 1996;40:2505\u201310.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR70","doi-asserted-by":"publisher","first-page":"134","DOI":"10.2165\/00003495-199958002-00033","volume":"58","author":"D Ince","year":"1999","unstructured":"Ince D, Aras R, Hooper DC. Mechanisms and frequency of resistance to gatifloxacin in comparison with ciprofloxacin in Staphylococcus aureus. Drugs. 1999;58:134\u20135.","journal-title":"Drugs."},{"key":"891_CR71","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2165\/00003495-199958002-00032","volume":"58","author":"D Ince","year":"1999","unstructured":"Ince D, Aras R, Hooper DC. Mechanisms and frequency of resistance to moxifloxacin in comparison with ciprofloxacin in Staphylococcus aureus. Drugs. 1999;58:132\u20133.","journal-title":"Drugs."},{"key":"891_CR72","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1128\/AAC.41.9.2059","volume":"41","author":"C Riesenfeld","year":"1997","unstructured":"Riesenfeld C, Everett M, Piddock LJV, Hall BG. Adaptive mutations produce resistance to ciprofloxacin. Antimicrob Agents Chemother. 1997;41:2059\u201360.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR73","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1128\/AAC.01826-10","volume":"55","author":"NR Morero","year":"2011","unstructured":"Morero NR, Monti MR, Argarana CE. Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators. Antimicrob Agents Chemother. 2011;55:3668\u201376.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR74","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/jac\/dki204","volume":"56","author":"L Drago","year":"2005","unstructured":"Drago L, De Vecchi E, Nicola L, Tocalli L, Gismondo MR. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin. J Antimicrob Chemother. 2005;56:353\u20139.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR75","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/jac\/43.suppl_2.31","volume":"43","author":"H Schedletzky","year":"1999","unstructured":"Schedletzky H, Wiedemann B, Heisig P. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus. J Antimicrob Chemother. 1999;43:31\u20137.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR76","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1007\/s00134-009-1417-4","volume":"35","author":"O Baldesi","year":"2009","unstructured":"Baldesi O, Michel F, Guervilly C, Embriaco N, Granfond A, La Scola B, et al. Bacterial ventilator-associated pneumonia: bronchoalveolar lavage results are not influenced by dilution. Intensive Care Med. 2009;35:1210\u20135.","journal-title":"Intensive Care Med."},{"key":"891_CR77","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1586\/17512433.2016.1172209","volume":"9","author":"NGL Jager","year":"2016","unstructured":"Jager NGL, van Hest RM, Lipman J, Taccone FS, Roberts JA. Therapeutic drug monitoring of anti-infective agents in critically ill patients. Expert Rev Clin Pharmacol. 2016;9:961\u201379.","journal-title":"Expert Rev Clin Pharmacol."},{"key":"891_CR78","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.diagmicrobio.2014.04.007","volume":"79","author":"TW Felton","year":"2014","unstructured":"Felton TW, Hope WW, Roberts JA. How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it? Diagn Microbiol Infect Dis. 2014;79:441\u20137.","journal-title":"Diagn Microbiol Infect Dis."},{"key":"891_CR79","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58:1072\u201383.","journal-title":"Clin Infect Dis."},{"key":"891_CR80","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","volume":"36","author":"JA Roberts","year":"2010","unstructured":"Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010;36:332\u20139.","journal-title":"Int J Antimicrob Agents."},{"key":"891_CR81","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/cc12844","volume":"17","author":"W Duszynska","year":"2013","unstructured":"Duszynska W, Taccone FS, Hurkacz M, Kowalska-Krochmal B, Wiela-Hojenska A, Kubler A. Therapeutic drug monitoring of amikacin in septic patients. Crit Care. 2013;17:10.","journal-title":"Crit Care."},{"key":"891_CR82","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1128\/AAC.01149-08","volume":"53","author":"F Pea","year":"2009","unstructured":"Pea F, Furlanut M, Negri C, Pavan F, Crapis M, Cristini F, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother. 2009;53:1863\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR83","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00687-17","author":"A Galar","year":"2017","unstructured":"Galar A, Valerio M, Munoz P, Alcala L, Garcia-Gonzalez X, Burillo A, et al. Systematic therapeutic drug monitoring for linezolid: variability and clinical impact. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.00687-17.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR84","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P745","author":"F Pea","year":"2011","unstructured":"Pea F, Cojutti P, Sbrojavacca R, Cadeo B, Cristini F, Bulfoni A, et al. TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother. 2011. https:\/\/doi.org\/10.1345\/aph.1P745.","journal-title":"Ann Pharmacother."},{"key":"891_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-016-0211-z","author":"N Allou","year":"2016","unstructured":"Allou N, Bouteau A, Allyn J, Snauwaert A, Valance D, Jabot J, et al. Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. Ann Intensive Care. 2016. https:\/\/doi.org\/10.1186\/s13613-016-0211-z.","journal-title":"Ann Intensive Care."},{"key":"891_CR86","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","volume":"42","author":"MH Abdul-Aziz","year":"2016","unstructured":"Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, Rai V, Wong KK, Hasan MS, et al. Beta-lactam infusion in severe sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016;42:1535\u201345.","journal-title":"Intensive Care Med."},{"key":"891_CR87","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1128\/AAC.05252-11","volume":"56","author":"GL Drusano","year":"2012","unstructured":"Drusano GL, Bonomo RA, Bahniuk N, Bulitta JB, VanScoy B, DeFiglio H, et al. Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56:231\u201342.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR88","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1128\/AAC.43.3.623","volume":"43","author":"ADM Kashuba","year":"1999","unstructured":"Kashuba ADM, Nafziger AN, Drusano GL, Bertino JS. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother. 1999;43:623\u20139.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR89","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1128\/AAC.01314-10","volume":"55","author":"GL Drusano","year":"2011","unstructured":"Drusano GL, Louie A. Optimization of aminoglycoside therapy. Antimicrob Agents Chemother. 2011;55:2528\u201331.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR90","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1128\/AAC.00441-10","volume":"54","author":"B Layeux","year":"2010","unstructured":"Layeux B, Taccone FS, Fagnoul D, Vincent JL, Jacobs F. Amikacin monotherapy for sepsis caused by pan resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54:4939\u201341.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR91","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijantimicag.2015.02.009","volume":"46","author":"C Roger","year":"2015","unstructured":"Roger C, Nucci B, Molinari N, Bastide S, Saissi G, Pradel G, et al. Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations. Int J Antimicrob Agents. 2015;46:21\u20137.","journal-title":"Int J Antimicrob Agents."},{"key":"891_CR92","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jac\/dkv291","volume":"71","author":"C Roger","year":"2016","unstructured":"Roger C, Nucci B, Louart B, Friggeri A, Knani H, Evrard A, et al. Impact of 30\u00a0mg\/kg amikacin and 8\u00a0mg\/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. J Antimicrob Chemother. 2016;71:208\u201312.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/cc8206","author":"CE Luyt","year":"2009","unstructured":"Luyt CE, Clavel M, Guntupalli K, Johannigman J, Kennedy JI, Wood C, et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care. 2009. https:\/\/doi.org\/10.1186\/cc8206.","journal-title":"Crit Care."},{"key":"891_CR94","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/ALN.0000000000001570","volume":"126","author":"C Sole-Lleonart","year":"2017","unstructured":"Sole-Lleonart C, Rouby JJ, Blot S, Poulakou G, Chastre J, Palmer LB, et al. Nebulization of antiinfective agents in invasively mechanically ventilated adults: a systematic review and meta-analysis. Anesthesiology. 2017;126:890\u2013908.","journal-title":"Anesthesiology."},{"key":"891_CR95","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1128\/AAC.6.4.465","volume":"6","author":"E Labovitz","year":"1974","unstructured":"Labovitz E, Levison ME, Kaye D. Single-dose daily gentamicin therapy in urinary tract infection. Antimicrob Agents Chemother. 1974;6:465\u201370.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR96","doi-asserted-by":"publisher","first-page":"E732","DOI":"10.1016\/j.ijid.2011.07.007","volume":"15","author":"AS Michalopoulos","year":"2011","unstructured":"Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15:E732\u20139.","journal-title":"Int J Infect Dis."},{"key":"891_CR97","doi-asserted-by":"publisher","first-page":"7170","DOI":"10.1128\/AAC.04955-14","volume":"59","author":"BD VanScoy","year":"2015","unstructured":"VanScoy BD, McCauley J, Ellis-Grosse EJ, Okusanya OO, Bhavnani SM, Forrest A, et al. Exploration of the pharmacokinetic-pharmacodynamic relationships for fosfomycin efficacy using an in vitro infection model. Antimicrob Agents Chemother. 2015;59:7170\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR98","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.ijantimicag.2006.05.019","volume":"28","author":"T Mazzei","year":"2006","unstructured":"Mazzei T, Cassetta MI, Fallani S, Arrigucci S, Novelli A. Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. Int J Antimicrob Agents. 2006;28:S35\u201341.","journal-title":"Int J Antimicrob Agents."},{"key":"891_CR99","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx441","author":"IJ Abbott","year":"2017","unstructured":"Abbott IJ, Meletiadis J, Belghanch I, Wijma RA, Kanioura L, Roberts JA, et al. Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model. J Antimicrob Chemother. 2017. https:\/\/doi.org\/10.1093\/jac\/dkx441.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR100","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13054-015-0818-8","volume":"19","author":"DM Roberts","year":"2015","unstructured":"Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother. 2012;67:255-68.","journal-title":"Crit Care"},{"key":"891_CR101","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1128\/AAC.01321-15","volume":"59","author":"SL Parker","year":"2015","unstructured":"Parker SL, Frantzeskaki F, Wallis SC, Diakaki C, Giamarellou H, Koulenti D, et al. Population pharmacokinetics of fosfomycin in critically ill patients. Antimicrob Agents Chemother. 2015;59:6471\u20136.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR102","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/jac\/dkq070","volume":"65","author":"V Matzi","year":"2010","unstructured":"Matzi V, Lindenmann J, Porubsky C, Kugler SA, Maier A, Dittrich P, et al. Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother. 2010;65:995\u20138.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR103","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1089\/jamp.2013.1100","volume":"27","author":"AB Montgomery","year":"2014","unstructured":"Montgomery AB, Vallance S, Abuan T, Tservistas M, Davies A. A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eflow (R) inline nebulizer system in mechanically ventilated patients. J Aerosol Med Pulm Drug Deliv. 2014;27:441\u20138.","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"key":"891_CR104","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","volume":"31","author":"PS McKinnon","year":"2008","unstructured":"McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T\u2009>\u2009MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31:345\u201351.","journal-title":"Int J Antimicrob Agents."},{"key":"891_CR105","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/jac\/dkf130","volume":"50","author":"VH Tam","year":"2002","unstructured":"Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002;50:425\u20138.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR106","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1128\/AAC.01956-15","volume":"60","author":"NJ Rhodes","year":"2016","unstructured":"Rhodes NJ, Kuti JL, Nicolau DP, Van Wart S, Nicasio AM, Liu JJ, et al. Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. Antimicrob Agents Chemother. 2016;60:1401\u201310.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR107","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ijantimicag.2014.12.018","volume":"45","author":"SL Aitken","year":"2015","unstructured":"Aitken SL, Altshuler J, Guervil DJ, Hirsch EB, Ostrosky-Zeichner LL, Ericsson CD, et al. Cefepime free minimum concentration to minimum inhibitory concentration (fC(min)\/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015;45:541\u20134.","journal-title":"Int J Antimicrob Agents."},{"key":"891_CR108","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1093\/jac\/dkw200","volume":"71","author":"JL Crandon","year":"2016","unstructured":"Crandon JL, Luyt C-E, Aubry A, Chastre J, Nicolau DP. Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence. J Antimicrob Chemother. 2016;71:2534.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR109","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.diagmicrobio.2009.03.031","volume":"64","author":"VH Tam","year":"2009","unstructured":"Tam VH, Ledesma KR, Schilling AN, Lim T-P, Yuan Z, Ghose R, et al. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing. Diagn Microbiol Infect Dis. 2009;64:427\u201333.","journal-title":"Diagn Microbiol Infect Dis."},{"key":"891_CR110","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/jac\/dks463","volume":"68","author":"SH Zinner","year":"2013","unstructured":"Zinner SH, Gilbert D, Greer K, Portnoy YA, Firsov AA. Concentration\u2013Resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. J Antimicrob Chemother. 2013;68:881\u20137.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR111","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1128\/AAC.02310-13","volume":"58","author":"BD VanScoy","year":"2014","unstructured":"VanScoy BD, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Jones RN, et al. Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model. Antimicrob Agents Chemother. 2014;58:6024\u201331.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR112","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1128\/AAC.00461-13","volume":"57","author":"B Vanscoy","year":"2013","unstructured":"Vanscoy B, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Forrest A, et al. Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. Antimicrob Agents Chemother. 2013;57:4134\u20138.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR113","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1128\/AAC.00080-14","volume":"58","author":"K Coleman","year":"2014","unstructured":"Coleman K, Levasseur P, Girard AM, Borgonovi M, Miossec C, Merdjan H, et al. Activities of ceftazidime and avibactam against \u03b2-lactamase-producing enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother. 2014;58:3366\u201372.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR114","doi-asserted-by":"publisher","first-page":"6137","DOI":"10.1128\/AAC.00851-12","volume":"56","author":"JL Crandon","year":"2012","unstructured":"Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, et al. Comparative In vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56:6137\u201346.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR115","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/ciw636","volume":"63","author":"RK Shields","year":"2016","unstructured":"Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime\u2013avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2016;63:1615\u20138.","journal-title":"Clin Infect Dis."},{"key":"891_CR116","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00134-004-2171-2","volume":"30","author":"E Boselli","year":"2004","unstructured":"Boselli E, Breilh D, Rimmele T, Poupelin JC, Saux MC, Chassard D, et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 2004;30:989\u201391.","journal-title":"Intensive Care Med."},{"key":"891_CR117","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13054-015-0818-8","volume":"19","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Liu X, Roberts JA, Nair P, Cole L, Roberts MS, et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Crit Care. 2015;19:84.","journal-title":"Crit Care"},{"key":"891_CR118","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1517\/17425255.2016.1141197","volume":"12","author":"KE Linder","year":"2016","unstructured":"Linder KE, Nicolau DP, Nailor MD. Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria. Exp Opin Drug Metab Toxicol. 2016;12:267\u201380.","journal-title":"Exp Opin Drug Metab Toxicol."},{"key":"891_CR119","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-016-1394-2","author":"F May","year":"2016","unstructured":"May F, El-Helali N, Timsit JF, Misset B. Absence of obvious link between supratherapeutic serum levels of beta lactams and clinical toxicity in ICU patients with acute renal failure treated with intermittent hemodialysis. Crit Care. 2016. https:\/\/doi.org\/10.1186\/s13054-016-1394-2.","journal-title":"Crit Care."},{"key":"891_CR120","first-page":"957","volume":"82","author":"C McDonald","year":"2016","unstructured":"McDonald C, Cotta MO, Little PJ, McWhinney B, Ungerer JPJ, Lipman J, et al. Is high-dose beta-lactam therapy associated with excessive drug toxicity in critically ill patients? Miner Anestesiol. 2016;82:957\u201365.","journal-title":"Miner Anestesiol"},{"key":"891_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/cc12705","author":"M Carlier","year":"2013","unstructured":"Carlier M, Carrette S, Roberts JA, Stove V, Verstraete A, Hoste E, et al. Meropenem and piperacillin\/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic\/pharmacodynamic target attainment when extended infusions are used? Crit Care. 2013. https:\/\/doi.org\/10.1186\/cc12705.","journal-title":"Crit Care."},{"key":"891_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/2110-5820-2-35","author":"FB Sime","year":"2012","unstructured":"Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA. Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? a systematic review. Ann Intensive Care. 2012. https:\/\/doi.org\/10.1186\/2110-5820-2-35.","journal-title":"Ann Intensive Care."},{"key":"891_CR123","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3109\/23744235.2015.1021831","volume":"47","author":"MO Cotta","year":"2015","unstructured":"Cotta MO, Gowen B, Truloff N, Bursle E, McWhinney B, Ungerer JPJ, et al. Even high-dose extended infusions may not yield desired concentrations of beta-lactams: the value of therapeutic drug monitoring. Infect Dis. 2015;47:739\u201342.","journal-title":"J Infect Dis."},{"key":"891_CR124","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1097\/CCM.0b013e318170ba21","volume":"36","author":"E Boselli","year":"2008","unstructured":"Boselli E, Breilh D, Rimmele T, Guillaume C, Xuereb F, Saux MC, et al. Alveolar concentrations of pipeyacillin\/tazobactam administered in continuous infusion to patients with ventilatoy-associated pneumonia. Crit Care Med. 2008;36:1500\u20136.","journal-title":"Crit Care Med."},{"key":"891_CR125","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2165\/11594090-000000000-00000","volume":"50","author":"KA Rodvold","year":"2011","unstructured":"Rodvold KA, George JM, Yoo L. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet. 2011;50:637\u201364.","journal-title":"Clin Pharmacokinet."},{"key":"891_CR126","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1097\/01.CCM.0000069734.38738.C8","volume":"31","author":"E Boselli","year":"2003","unstructured":"Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, et al. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med. 2003;31:2102\u20136.","journal-title":"Crit Care Med."},{"key":"891_CR127","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1128\/AAC.01361-08","volume":"53","author":"D Plachouras","year":"2009","unstructured":"Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother. 2009;53:3430\u20136.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR128","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1128\/AAC.01733-10","volume":"55","author":"SM Garonzik","year":"2011","unstructured":"Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284\u201394.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR129","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/jac\/dkm511","volume":"61","author":"PJ Bergen","year":"2008","unstructured":"Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother. 2008;61:636\u201342.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR130","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/cid\/cis286","volume":"54","author":"L Dalfino","year":"2012","unstructured":"Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? a preliminary study. Clin Infect Dis. 2012;54:1720\u20136.","journal-title":"Clin Infect Dis."},{"key":"891_CR131","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s00134-012-2628-7","volume":"38","author":"ZE Athanassa","year":"2012","unstructured":"Athanassa ZE, Markantonis SL, Fousteri MZF, Myrianthefs PM, Boutzouka EG, Tsakris A, et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med. 2012;38:1779\u201386.","journal-title":"Intensive Care Med."},{"key":"891_CR132","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1378\/chest.10-0463","volume":"138","author":"R Imberti","year":"2010","unstructured":"Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest. 2010;138:1333\u20139.","journal-title":"Chest."},{"key":"891_CR133","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s10096-016-2736-3","volume":"35","author":"H Nordqvist","year":"2016","unstructured":"Nordqvist H, Nilsson LE, Claesson C. Mutant prevention concentration of colistin alone and in combination with rifampicin for multidrug-resistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis. 2016;35:1845\u201350.","journal-title":"Eur J Clin Microbiol."},{"key":"891_CR134","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1128\/AAC.02927-15","volume":"60","author":"SE Cheah","year":"2016","unstructured":"Cheah SE, Li J, Tsuji BT, Forrest A, Bulitta JB, Nation RL. Colistin and polymyxin b dosage regimens against Acinetobacter baumannii: differences in activity and the emergence of resistance. Antimicrob Agents Chemother. 2016;60:3921\u201333.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR135","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1128\/AAC.02831-15","volume":"60","author":"BT Tsuji","year":"2016","unstructured":"Tsuji BT, Landersdorfer CB, Lenhard JR, Cheah SE, Thamlikitkul V, Rao GG, et al. Paradoxical effect of polymyxin b: high drug exposure amplifies resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60:3913\u201320.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR136","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000109868","volume":"81","author":"R Sauermann","year":"2008","unstructured":"Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval. Pharmacology. 2008;81:79\u201391.","journal-title":"Pharmacology"},{"key":"891_CR137","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1128\/AAC.00247-06","volume":"50","author":"M Benvenuto","year":"2006","unstructured":"Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3245\u20139.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR138","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s40265-016-0610-3","volume":"76","author":"A D\u2019Avolio","year":"2016","unstructured":"D\u2019Avolio A, Pensi D, Baietto L, Pacini G, Di Perri G, De Rosa FG. Daptomycin pharmacokinetics and pharmacodynamics in septic and critically ill patients. Drugs. 2016;76:1161\u201374.","journal-title":"Drugs."},{"key":"891_CR139","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1128\/AAC.00102-08","volume":"52","author":"WE Rose","year":"2008","unstructured":"Rose WE, Leonard SN, Rybak MJ. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008;52:3061\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR140","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1128\/AAC.49.4.1664-1665.2005","volume":"49","author":"K Sabol","year":"2005","unstructured":"Sabol K, Patterson JE, Lewis Ii JS, Owens A, Cadena J, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother. 2005;49:1664\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"891_CR141","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1093\/cid\/cit582","volume":"57","author":"M Falcone","year":"2013","unstructured":"Falcone M, Russo A, Venditti M, Novelli A, Pai MP. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2013;57:1568\u201376.","journal-title":"Clin Infect Dis."},{"key":"891_CR142","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1128\/AAC.37.3.483","volume":"37","author":"GL Drusano","year":"1993","unstructured":"Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993;37:483\u201390.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR143","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1128\/AAC.00334-06","volume":"51","author":"VH Tam","year":"2007","unstructured":"Tam VH, Louie A, Deziel MR, Liu WG, Leary R, Drusano GL. Bacterial-population responses to drug-selective pressure: Examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis. 2005;192:420\u20138.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR144","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jcrc.2007.11.011","volume":"23","author":"ARH van Zanten","year":"2008","unstructured":"van Zanten ARH, Polderman KH, van Geijlswijk IM, van der Meer GYG, Schouten MA, Girbes ARJ. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care. 2008;23:422\u201330.","journal-title":"J Crit Care."},{"key":"891_CR145","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/fcp.12156","volume":"29","author":"Y Cazaubon","year":"2015","unstructured":"Cazaubon Y, Bourguignon L, Goutelle S, Martin O, Maire P, Ducher M. Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study. Fundam Clin Pharmacol. 2015;29:615\u201324.","journal-title":"Fundam Clin Pharmacol."},{"key":"891_CR146","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1128\/AAC.42.9.2235","volume":"42","author":"J Lipman","year":"1998","unstructured":"Lipman J, Scribante J, Gous AGS, Hon H, Tshukutsoane S, The Baragwanath Ciprofloxacin Study G. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. Antimicrob Agents Chemother. 1998;42:2235\u20139.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR147","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/jac\/dkg401","volume":"52","author":"SH Zinner","year":"2003","unstructured":"Zinner SH, Lubenko IY, Gilbert D, Simmons K, Zhao XL, Drlica K, et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother. 2003;52:616\u201322.","journal-title":"J Antimicrob Chemother"},{"key":"891_CR148","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00134-010-1864-y","volume":"36","author":"MW Pletz","year":"2010","unstructured":"Pletz MW, Bloos F, Burkhardt O, Brunkhorst FM, Bode-Boger SM, Martens-Lobenhoffer J, et al. Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. Intensive Care Med. 2010;36:979\u201383.","journal-title":"Intensive Care Med."},{"key":"891_CR149","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1128\/AAC.47.3.1088-1095.2003","volume":"47","author":"AP MacGowan","year":"2003","unstructured":"MacGowan AP, Rogers CA, Holt HA, Bowker KE. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 2003;47:1088\u201395.","journal-title":"Antimicrob Agents Chemother."},{"issue":"Suppl 4","key":"891_CR150","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1086\/382690","volume":"38","author":"DL Paterson","year":"2004","unstructured":"Paterson DL. \u201cCollateral damage\u201d from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004;38 Suppl 4:S341\u20135.","journal-title":"Clin Infect Dis."},{"key":"891_CR151","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1093\/jac\/dku283","volume":"69","author":"V de Lastours","year":"2014","unstructured":"de Lastours V, Chau F, Roy C, Larroque B, Fantin B. Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone. J Antimicrob Chemother. 2014;69:3393\u2013400.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR152","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1086\/600122","volume":"200","author":"B Fantin","year":"2009","unstructured":"Fantin B, Duval X, Massias L, Alavoine L, Chau F, Retout S, et al. Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J Infect Dis. 2009;200:390\u20138.","journal-title":"J Infect Dis."},{"key":"891_CR153","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1086\/314888","volume":"180","author":"C Janoir","year":"1999","unstructured":"Janoir C, Podglajen I, Kitzis MD, Poyart C, Gutmann L. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and Viridans streptococci and genomic organization of the parE-parC region in S-mitis. J Infect Dis. 1999;180:555\u20138.","journal-title":"J Infect Dis."},{"key":"891_CR154","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1128\/AAC.05664-11","volume":"56","author":"AM Nicasio","year":"2012","unstructured":"Nicasio AM, Bulitta JB, Lodise TP, D\u2019Hondt RE, Kulawy R, Louie A, et al. Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model. Antimicrob Agents Chemother. 2012;56:682\u20136.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR155","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1128\/AAC.00362-12","volume":"57","author":"DG Lee","year":"2013","unstructured":"Lee DG, Murakami Y, Andes DR, Craig WA. Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) cfu injected into opposite thighs of neutropenic mice. Antimicrob Agents Chemother. 2013;57:1434\u201341.","journal-title":"Antimicrob Agents Chemother"},{"key":"891_CR156","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1086\/381093","volume":"38","author":"PGP Charles","year":"2004","unstructured":"Charles PGP, Ward PB, Johnson PDR, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38:448\u201351.","journal-title":"Clin Infect Dis."},{"key":"891_CR157","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jac\/dkl030","volume":"57","author":"G Sakoulas","year":"2006","unstructured":"Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother. 2006;57:699\u2013704.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR158","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/1060028014556813","volume":"49","author":"JM Rosini","year":"2015","unstructured":"Rosini JM, Laughner J, Levine BJ, Papas MA, Reinhardt JF, Jasani NB. A randomized trial of loading vancomycin in the emergency department. Ann Pharmacother. 2015;49:6\u201313.","journal-title":"Ann Pharmacother."},{"key":"891_CR159","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1128\/AAC.01472-10","volume":"55","author":"S Zelenitsky","year":"2011","unstructured":"Zelenitsky S, Alkurdi N, Weber Z, Ariano R, Zhanel G. Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model. Antimicrob Agents Chemother. 2011;55:3627\u201330.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR160","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ijantimicag.2015.04.013","volume":"46","author":"T Hanrahan","year":"2015","unstructured":"Hanrahan T, Whitehouse T, Lipman J, Roberts JA. Vancomycin-associated nephrotoxicity: a meta-analysis of administration by continuous versus intermittent infusion. Int J Antimicrob Agents. 2015;46:249\u201353.","journal-title":"Int J Antimicrob Agents."},{"key":"891_CR161","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1128\/AAC.05473-11","volume":"56","author":"M Hagihara","year":"2012","unstructured":"Hagihara M, Wiskirchen DE, Kuti JL, Nicolau DP. In Vitro Pharmacodynamics of Vancomycin and Cefazolin Alone and in Combination against Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2012;56:202\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR162","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.clinthera.2014.06.027","volume":"36","author":"TJ Dilworth","year":"2014","unstructured":"Dilworth TJ, Leonard SN, Vilay AM, Mercier RC. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic\/pharmacodynamic model. Clin Ther 2014;36:1334\u201344.","journal-title":"Clin Ther."},{"key":"891_CR163","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1128\/AAC.43.7.1747","volume":"43","author":"MW Climo","year":"1999","unstructured":"Climo MW, Patron RL, Archer GL. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother. 1999;43:1747\u201353.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR164","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/cid\/civ808","volume":"62","author":"JS Davis","year":"2016","unstructured":"Davis JS, Sud A, O\u2019Sullivan MVN, Robinson JO, Ferguson PE, Foo H, et al. Combination of vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis. 2016;62:173\u201380.","journal-title":"Clin Infect Dis."},{"key":"891_CR165","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1128\/AAC.01194-06","volume":"51","author":"LML Boak","year":"2007","unstructured":"Boak LML, Rayner CR, Nation RL. Pharmacokinetic\/Pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob Agents Chemother. 2007;51:1287\u201392.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR166","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1001\/jama.2010.757","volume":"303","author":"MS Garcia","year":"2010","unstructured":"Garcia MS, De la Torre MA, Morales G, Pelaez B, Tolon MJ, Domingo S, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA. 2010;303:2260\u20134.","journal-title":"JAMA."},{"key":"891_CR167","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/01.inf.0000219401.70804.1a","volume":"25","author":"SM Roberts","year":"2006","unstructured":"Roberts SM, Freeman AF, Harrington SM, Holland SM, Murray PR, Zelazny AM. Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatr Infect Dis J. 2006;25:562\u20134.","journal-title":"Pediatr Infect Dis J."},{"key":"891_CR168","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/cc13984","volume":"18","author":"M Zoller","year":"2014","unstructured":"Zoller M, Maier B, Hornuss C, Neugebauer C, Dobbeler G, Nagel D, et al. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care. 2014;18:11.","journal-title":"Crit Care."},{"key":"891_CR169","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.ijantimicag.2013.02.020","volume":"41","author":"D Cattaneo","year":"2013","unstructured":"Cattaneo D, Orlando G, Cozzi V, Cordier L, Baldelli S, Merli S, et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents. 2013;41:586\u20139.","journal-title":"Int J Antimicrob Agents."},{"key":"891_CR170","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/bcpt.12797","volume":"121","author":"F Pea","year":"2017","unstructured":"Pea F, Cojutti PG, Baraldo M. A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients? Basic Clin Pharmacol Toxicol. 2017;121:303\u20138.","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"891_CR171","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1371\/journal.pcbi.1004689","volume":"12","author":"T Day","year":"2016","unstructured":"Day T, Read AF. Does high-dose antimicrobial chemotherapy prevent the evolution of resistance? PLoS Comput Biol. 2016;12:20.","journal-title":"PLoS Comput Biol."},{"key":"891_CR172","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01011-16","author":"R Yadav","year":"2017","unstructured":"Yadav R, Bulitta JB, Nation RL, Landersdorfer CB. Optimization of synergistic combination regimens against carbapenem- and aminoglycoside-resistant clinical Pseudomonas aeruginosa isolates via mechanism-based pharmacokinetic\/pharmacodynamic modeling. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.01011-16.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR173","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1128\/AAC.04379-14","volume":"59","author":"R Yadav","year":"2015","unstructured":"Yadav R, Landersdorfer CB, Nation RL, Boyce JD, Bulitta JB. Novel Approach To Optimize Synergistic Carbapenem-Aminoglycoside Combinations against Carbapenem-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59:2286\u201398.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR174","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1128\/AAC.01680-08","volume":"53","author":"GL Drusano","year":"2009","unstructured":"Drusano GL, Liu WG, Fregeau C, Kulawy R, Louie A. Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrob Agents Chemother. 2009;53:2266\u201373.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR175","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01763-16","author":"FB Sime","year":"2016","unstructured":"Sime FB, Johnson A, Whalley S, Santoyo-Castelazo A, Montgomery AB, Walters KA, et al. Pharmacodynamics of aerosolized fosfomycin and amikacin against resistant clinical isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a hollow-fiber infection model: experimental basis for combination therapy. Antimicrob Agents Chemother. 2016. https:\/\/doi.org\/10.1128\/AAC.01763-16.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR176","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0732-8893(00)00162-0","volume":"38","author":"DS Burgess","year":"2000","unstructured":"Burgess DS, Hastings RW. Activity of piperacillin\/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill. Diagn Microbiol Infect Dis. 2000;38:37\u201341.","journal-title":"Diagn Microbiol Infect Dis."},{"key":"891_CR177","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/jac\/19.3.321","volume":"19","author":"PH Chandrasekar","year":"1987","unstructured":"Chandrasekar PH, Crane LR, Bailey EJ. Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients. J Antimicrob Chemother. 1987;19:321\u20139.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR178","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1086\/430912","volume":"41","author":"IA Bliziotis","year":"2005","unstructured":"Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis. 2005;41:149\u201358.","journal-title":"Clin Infect Dis."},{"key":"891_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.09.020","author":"DSY Ong","year":"2017","unstructured":"Ong DSY, van Werkhoven CH, Cremer OL, Thwaites GE, Bonten MJM. Is a randomized trial of a short course of aminoglycoside added to beta-lactam antibiotics for empirical treatment in critically ill patients with sepsis justified? Clin Microbiol Infect. 2017. https:\/\/doi.org\/10.1016\/j.cmi.2017.09.020.","journal-title":"Clin Microbiol Infect."},{"key":"891_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.12.019","author":"A Heffernan","year":"2018","unstructured":"Heffernan A, Lipman J, Roberts J. Is a randomized trial of a short course of aminoglycoside added to beta lactam antibiotics for empirical treatment in critically ill patients with sepsis justified? Clin Microbiol Infect. 2018. https:\/\/doi.org\/10.1016\/j.cmi.2017.12.019.","journal-title":"Clin Microbiol Infect."},{"key":"891_CR181","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/jac\/dkg238","volume":"51","author":"MA Dawis","year":"2003","unstructured":"Dawis MA, Isenberg HD, France KA, Jenkins SG. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms. J Antimicrob Chemother. 2003;51:1203-\u20131.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR182","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0732-8893(02)00420-0","volume":"44","author":"DS Burgess","year":"2002","unstructured":"Burgess DS, Nathisuwan S. Cefepime, piperacillin\/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2002;44:35\u201341.","journal-title":"Diagn Microbiol Infect Dis."},{"key":"891_CR183","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molcel.2010.01.003","volume":"37","author":"MA Kohanski","year":"2010","unstructured":"Kohanski MA, DePristo MA, Collins JJ. Sublethal Antibiotic Treatment Leads to Multidrug Resistance via Radical-Induced Mutagenesis. Molecular Cell. 2010;37:311\u201320.","journal-title":"Molecular Cell."},{"key":"891_CR184","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1128\/AAC.01131-09","volume":"54","author":"KM Wener","year":"2010","unstructured":"Wener KM, Schechner V, Gold HS, Wright SB, Carmeli Y. Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella Species in hospitalized patients. Antimicrob Agents Chemother. 2010;54:2010\u20136.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR185","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1111\/j.1469-0691.2010.03349.x","volume":"17","author":"P Cassier","year":"2011","unstructured":"Cassier P, Lallechere S, Aho S, Astruc K, Neuwirth C, Piroth L, et al. Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M beta-lactamase-producing Escherichia coli: a case\u2013control study in a French teaching hospital. Clin Microbiol Infect. 2011;17:1746\u201351.","journal-title":"Clin Microbiol Infect."},{"key":"891_CR186","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ajic.2014.01.005","volume":"42","author":"RC Goldstein","year":"2014","unstructured":"Goldstein RC, Husk G, Jodlowski T, Mildvan D, Perlman DC, Ruhe JJ. Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: The risk of subsequent isolation of multidrug-resistant organisms. Am J Infect Control. 2014;42:539\u201341.","journal-title":"Am J Infect Control."},{"key":"891_CR187","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1128\/AAC.00103-06","volume":"50","author":"J Li","year":"2006","unstructured":"Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2006;50:2946\u201350.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR188","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ijantimicag.2016.07.024","volume":"48","author":"JR Lenhard","year":"2016","unstructured":"Lenhard JR, Gall JS, Bulitta JB, Thamlikitkul V, Landersdorfer CB, Forrest A, et al. Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2016;48:719\u201324.","journal-title":"Int J Antimicrob Agents."},{"key":"891_CR189","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1128\/AAC.05028-11","volume":"55","author":"PJ Bergen","year":"2011","unstructured":"Bergen PJ, Forrest A, Bulitta JB, Tsuji BT, Sidjabat HE, Paterson DL, et al. Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula. Antimicrob Agents Chemother. 2011;55:5134\u201342.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR190","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1128\/AAC.02377-15","volume":"60","author":"NS Ly","year":"2016","unstructured":"Ly NS, Bulman ZP, Bulitta JB, Baron C, Rao GG, Holden PN, et al. Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60:2870\u201380.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR191","doi-asserted-by":"publisher","first-page":"6575","DOI":"10.1128\/AAC.00494-15","volume":"59","author":"MH Rigatto","year":"2015","unstructured":"Rigatto MH, Vieira FJ, Antochevis LC, Behle TF, Lopes NT, Zavascki AP. Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections. Antimicrob Agents Chemother. 2015;59:6575\u201380.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR192","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ijantimicag.2017.01.007","volume":"49","author":"XJ Cai","year":"2017","unstructured":"Cai XJ, Yang Z, Dai JQ, Chen K, Zhang LD, Ni WT, et al. Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Int J Antimicrob Agents. 2017;49:609\u201316.","journal-title":"Int J Antimicrob Agents."},{"key":"891_CR193","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01815-17","author":"JK Diep","year":"2017","unstructured":"Diep JK, Sharma R, Ellis-Grosse EJ, Abboud CS, Rao GG. Polymyxin B and ZTI-01 (fosfomycin for injection) against KPC-producing Klebsiella pneumoniae: evaluation of activity and emergence of resistance. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.01815-17.","journal-title":"Antimicrob Agents Chemother."},{"key":"891_CR194","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1093\/jac\/dkw115","volume":"71","author":"CC Walsh","year":"2016","unstructured":"Walsh CC, Landersdorfer CB, McIntosh MP, Peleg AY, Hirsch EB, Kirkpatrick CM, et al. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. J Antimicrob Chemother. 2016;71:2218\u201329.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR195","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1093\/jac\/dkw293","volume":"71","author":"GG Rao","year":"2016","unstructured":"Rao GG, Ly NS, Bulitta JB, Soon RL, San Roman MD, Holden PN, et al. Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies. J Antimicrob Chemother. 2016;71:3148-\u201356.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR196","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ijantimicag.2016.06.006","volume":"48","author":"GG Rao","year":"2016","unstructured":"Rao GG, Ly NS, Diep J, Forrest A, Bulitta JB, Holden PN, et al. Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. Int J Antimicrob Agents. 2016;48:331\u20136.","journal-title":"Int J Antimicrob Agents."},{"key":"891_CR197","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ijantimicag.2009.12.022","volume":"35","author":"JM Entenza","year":"2010","unstructured":"Entenza JM, Giddey M, Vouillamoz J, Moreillon P. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin\/clavulanic acid or ampicillin. Int J Antimicrob Agents. 2010;35:451\u20136.","journal-title":"Int J Antimicrob Agents."},{"key":"891_CR198","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/jama.286.1.49","volume":"286","author":"SJ Schrag","year":"2001","unstructured":"Schrag SJ, Pena C, Fernandez J, Sanchez J, Gomez V, Perez E, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA. 2001;286:49\u201356.","journal-title":"JAMA."},{"key":"891_CR199","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jama.279.5.365","volume":"279","author":"D Guillemot","year":"1998","unstructured":"Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vauzelle-Kervroedan F, et al. Low dosage and long treatment duration of beta-lactam\u2014risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA. 1998;279:365\u201370.","journal-title":"JAMA."},{"key":"891_CR200","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1086\/374556","volume":"36","author":"JJ Ruhe","year":"2003","unstructured":"Ruhe JJ, Hasbun R. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis. 2003;36:1132-\u20138.","journal-title":"Clin Infect Dis."},{"key":"891_CR201","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/jac\/dkm141","volume":"60","author":"S Hillier","year":"2007","unstructured":"Hillier S, Roberts Z, Dunstan F, Butler C, Howard A, Palmer S. Prior antibiotics and risk of antibiotic-resistant community-acquired urinary tract infection: a case-control study. J Antimicrob Chemother. 2007;60:92\u20139.","journal-title":"J Antimicrob Chemother."},{"key":"891_CR202","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","volume":"290","author":"J Chastre","year":"2003","unstructured":"Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290:2588\u201398.","journal-title":"JAMA."},{"key":"891_CR203","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-017-0296-z","author":"E Yusuf","year":"2017","unstructured":"Yusuf E, Van Herendael B, Verbrugghe W, Ieven M, Goovaerts E, Bergs K, et al. Emergence of antimicrobial resistance to Pseudomonas aeruginosa in the intensive care unit: association with the duration of antibiotic exposure and mode of administration. Ann Intensive Care. 2017. https:\/\/doi.org\/10.1186\/s13613-017-0296-z.","journal-title":"Ann Intensive Care."},{"key":"891_CR204","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1056\/NEJMoa1411162","volume":"372","author":"RG Sawyer","year":"2015","unstructured":"Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, et al. Trial of Short-Course Antimicrobial Therapy for Intraabdominal Infection. N Engl J Med. 2015;372:1996\u20132005.","journal-title":"N Engl J Med."},{"key":"891_CR205","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00384-015-2161-6","volume":"30","author":"DS Lee","year":"2015","unstructured":"Lee DS, Ryu JA, Chung CR, Yang J, Jeon K, Suh GY, et al. Risk factors for acquisition of multidrug-resistant bacteria in patients with anastomotic leakage after colorectal cancer surgery. Int J Colorectal Dis. 2015;30:497\u2013504.","journal-title":"Int J Colorectal Dis."},{"key":"891_CR206","doi-asserted-by":"publisher","DOI":"10.1186\/cc8872","author":"C Pierrakos","year":"2010","unstructured":"Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010. https:\/\/doi.org\/10.1186\/cc8872.","journal-title":"Crit Care."},{"key":"891_CR207","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1586\/1744666X.2014.949675","volume":"10","author":"M Sandquist","year":"2014","unstructured":"Sandquist M, Wong HR. Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment. Exp Rev Clin Immunol. 2014;10:1349\u201356.","journal-title":"Exp Rev Clin Immunol."},{"key":"891_CR208","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2110-5820-3-22","volume":"3","author":"A-M Dupuy","year":"2013","unstructured":"Dupuy A-M, Philippart F, P\u00e9an Y, Lasocki S, Charles P-E, Chalumeau M, et al. Role of biomarkers in the management of antibiotic therapy: an expert panel review: I \u2013 currently available biomarkers for clinical use in acute infections. Ann Intensive Care. 2013;3:1\u20138.","journal-title":"Ann Intensive Care."},{"key":"891_CR209","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1473-3099(12)70323-7","volume":"13","author":"C Wacker","year":"2013","unstructured":"Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13:426\u201335.","journal-title":"Lancet Infect DIs."},{"key":"891_CR210","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1097\/01.CCM.0000226413.54364.36","volume":"34","author":"B Uzzan","year":"2006","unstructured":"Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006;34:1996\u20132003.","journal-title":"Crit Care Med."},{"key":"891_CR211","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S1473-3099(07)70052-X","volume":"7","author":"BMP Tang","year":"2007","unstructured":"Tang BMP, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis. 2007;7:210\u20137.","journal-title":"Lancet Infect Dis."},{"key":"891_CR212","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.ajem.2016.03.065","volume":"34","author":"Y van der Does","year":"2016","unstructured":"van der Does Y, Rood PPM, Haagsma JA, Patka P, van Gorp ECM, Limper M. Procalcitonin-guided therapy for the initiation of antibiotics in the ED: a systematic review. Am J Emerg Med. 2016;34:1286\u201393.","journal-title":"Am J Emerg Med."},{"key":"891_CR213","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2096","author":"C Costelloe","year":"2010","unstructured":"Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ. 2010. https:\/\/doi.org\/10.1136\/bmj.c2096.","journal-title":"BMJ."},{"key":"891_CR214","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0140-6736(05)70799-6","volume":"365","author":"H Goossens","year":"2005","unstructured":"Goossens H, Ferech M, Stichele RV, Elseviers M, Grp EP. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365:579\u201387.","journal-title":"Lancet."},{"key":"891_CR215","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","volume":"16","author":"E de Jong","year":"2016","unstructured":"de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16:819\u201327.","journal-title":"Lancet Infect Dis."},{"key":"891_CR216","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1097\/CCM.0b013e3181f17bf9","volume":"38","author":"P Kopterides","year":"2010","unstructured":"Kopterides P. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med. 2010;38:2229\u201341.","journal-title":"Crit Care Med."},{"key":"891_CR217","doi-asserted-by":"publisher","DOI":"10.1186\/cc13157","author":"A Prkno","year":"2013","unstructured":"Prkno A, Wacker C, Brunkhorst FM, Schlattmann P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock\u2014a systematic review and meta-analysis. Crit Care. 2013. https:\/\/doi.org\/10.1186\/cc13157.","journal-title":"Crit Care."},{"key":"891_CR218","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1001\/archinternmed.2011.318","volume":"171","author":"P Schuetz","year":"2011","unstructured":"Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med. 2011;171:1322\u201331.","journal-title":"Arch Intern Med."},{"key":"891_CR219","first-page":"CD007498","volume":"10","author":"P Schuetz","year":"2012","unstructured":"Schuetz P, M\u00fcller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2012;10:CD007498.","journal-title":"Cochrane Database Syst Rev."},{"key":"891_CR220","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.04.04","author":"D Nora","year":"2017","unstructured":"Nora D, Salluh J, Martin-Loeches I, P\u00f3voa P. Biomarker-guided antibiotic therapy\u2014strengths and limitations. Ann Transl Med. 2017. https:\/\/doi.org\/10.21037\/atm.2017.04.04.","journal-title":"Ann Transl Med."},{"key":"891_CR221","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1086\/421997","volume":"39","author":"L Simon","year":"2004","unstructured":"Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infec Dis. 2004;39:206\u201317.","journal-title":"Clin Infec Dis."},{"key":"891_CR222","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1378\/chest.123.6.2043","volume":"123","author":"SM Lobo","year":"2003","unstructured":"Lobo SM, Lobo FR, Bota DP, Lopes-Ferreira F, Soliman HM, Melot C, et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest. 2003;123:2043\u20139.","journal-title":"Chest."},{"key":"891_CR223","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1097\/CCM.0b013e31828e969f","volume":"41","author":"CF Oliveira","year":"2013","unstructured":"Oliveira CF, Botoni FA, Oliveira CR, Silva CB, Pereira HA, Serufo JC, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Crit Care Med. 2013;41:2336\u201343.","journal-title":"Crit Care Med."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-018-0891-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0891-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0891-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:05:50Z","timestamp":1744715150000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-018-0891-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,22]]},"references-count":223,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0891-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,22]]},"assertion":[{"value":"22 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Jason Roberts would like to declare collaborations with MSD, Bayer, Astellas, Pfizer, bioMerieux and Accelerate Diagnostics but none of which are considered relevant to the content of this paper. Aaron Heffernan, Fekade Sime and Jeffrey Lipman have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}